Feature | Heart Failure | September 01, 2015

Automated Pulmonary Congestion Alert No Benefit In Heart Failure Trial

Patient adherence primary obstacle to improved outcomes

Medtronic, OPTILINK, OptiVol, ICD, pulmonary congestion, ESC 2015

September 1, 2015 — Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with implantable cardioverter defibrillators (ICDs), according to results of the OPTILINK HF trial.

The findings, presented at the European Society of Cardiology (ESC) Congress 2015, “highlight the challenges and obstacles involved in ICD-based telemonitoring for heart failure (HF),” noted the study’s principal investigator Michael Böhm, M.D., from Saarland University Hospital in Homburg, Germany. 

“Given the considerable, and largely unmitigated burden of HF, the potential for telemonitoring to improve the management of patients with HF is substantial,” said Böhm. “However, in our trial ICD-based telemonitoring did not increase appropriate interventions, despite intensive instruction of patients and physicians in the clinical trial setting,” he suggested.

Because hospital admissions are frequently preceded by increased pulmonary congestion in heart failure patients, the trial used special ICDs that allow for automatic transmission of alerts to a patient’s doctor when this happens. The alert is transmitted from the ICD through a telemedicine monitor that patients have connected to the internet at home.

A total of 1,002 patients received these ICDs, with 505 patients randomly assigned to have the automated transmission turned on, and 497 patients to have it turned off (standard care). 

“If there was an alert, the physician called the patient, provided him with an exact care alert questionnaire, and increased therapies if necessary. Based on a strict algorithm patients were potentially seen or admitted to the hospital and care was initiated,” explained Böhm. 

During the study period there were 1,748 “fluid threshold crossings” which triggered an alert. Three quarters (76 percent) of these alerts were successfully transmitted from the patient’s ICD to the physician, with the remaining 24 percent deemed unsuccessful because the patient was either already in the hospital, on vacation without the monitor or offline.

Medical action was taken by physicians for 30 percent of the successful transmissions – most of these involving medication changes. In the 70 percent of cases where no medical action was taken, the reason was that although the alert indicated a fluid threshold crossing, it was not considered clinically actionable because the patient did not indicate visible signs or symptoms of worsening HF, explained Böhm.

After 18 months of follow-up there was no significant difference between groups in primary endpoint, which was a composite of all-cause death and cardiovascular hospitalization.

The primary outcome occurred in 227 patients (45 percent) in the intervention arm compared with 239 patients (48.1 percent) in the control arm (hazard ratio, 0.87; 95 percent confidence interval [CI], 0.72 to 1.04; p=0.13). There were 59 (11.7 percent) deaths in the intervention arm and 63 (12.7%) in the control arm group (hazard ratio, 0.89; 95 percent CI, 0.62 to 1.28; p=0.52). 

The obstacles to ICD-based HF telemonitoring identified in OPTILINK HF would likely be even more pronounced in a real-life clinical setting, noted Böhm. “Improved outcomes would require better patient adherence in terms of being online all the time,” he said.

For more information: www.escardio.org


Related Content

News | Heart Failure

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in ...

Home September 29, 2022
Home
News | Heart Failure

September 28, 2022 — A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are ...

Home September 28, 2022
Home
News | Heart Failure

September 19, 2022 — A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has ...

Home September 19, 2022
Home
News | Heart Failure

September 15, 2022 — Today, aortic stenosis (AS) is one of the most common and serious valve disease problems [1]. It ...

Home September 15, 2022
Home
News | Heart Failure

September 14, 2022 — Minimally invasive, catheter-based transcatheter aortic valve replacement (TAVR) has revolutionized ...

Home September 14, 2022
Home
News | Heart Failure

September 2, 2022 — Dapagliflozin reduces the risk of cardiovascular death or worsening heart failure in heart failure ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure ...

Home September 02, 2022
Home
News | Heart Failure

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) ...

Home August 29, 2022
Home
News | Heart Failure

August 24, 2022 — Patients diagnosed with moderate aortic stenosis and congestive heart failure may qualify to ...

Home August 24, 2022
Home
Subscribe Now